natgillin/translations-raw huggingface dataset:
Further PEC refinement for the direct excretion scenario considering that peak excretion of total residues occurred on day 5 after administration and accounted for 7.8% of the administered dose, as well as based on sediment partitioning lead to a PECsw-refined-direct of 0.00049 µg/l, resulting in a RQ for Daphnia (4.9) still higher than 1. 
Nadaljnje izboljšanje PKO za scenarij neposrednega izločanja ob upoštevanju, da je bilo izločanje celotnih ostankov največje 5. dan po dajanju zdravila in je ustrezalo 7,8 % uporabljenega odmerka, ter na podlagi porazdelitve sedimenta je privedlo do izboljšane PKOpovršinske vode za neposredno izločanje 0,00049 µg/l, kar pomeni, da je količnik tveganja za organizem Daphnia (4,9) še vedno večji od 1.
• On the basis of the residue depletion data in cattle submitted with the application is was considered that a 70-day withdrawal period should be established in cattle meat and offal; 
• na osnovi podatkov o izločanju ostankov pri govedu, ki so bili predloženi z vlogo, je bilo sprejeto stališče, da je treba za meso in drobovino pri govedu določiti karenco 70 dni;
A Daphnia magna reproduction study for conducting a Tier B assessment was not submitted in the ERA. 
Študija vpliva na sposobnost razmnoževanja Daphnia magna za izvedbo ocene v stopnji B v okviru ocene tveganja za okolje ni bila predložena.
Pigs - 1 ml per 33 kg bodyweight 
Prašiči - 1 ml na 33 kg telesne mase
The sample sizes of injection sites were not reported and surrounding ring samples were not collected. 
O velikosti vzorcev z mest injiciranja niso poročali, prav tako niso bili zbrani vzorci sosednjega tkiva.
Injection site was the tissue with the slowest rate of residue depletion and therefore results from the injection site are the basis from which derive the withdrawal period. 
Mesto injiciranja je bilo tkivo z najnižjo hitrostjo izločanja ostankov, zato so rezultati z mesta injiciranja osnova za določitev karence.
The CVMP was asked to give its opinion on the concerns raised by the Concerned Member States and to conclude on the benefit/risk balance for Prontax 10 mg/ml solution for injection for cattle, sheep, and pigs. 
CVMP je bil naprošen, da poda mnenje v zvezi z zadržki, ki so jih je izrazile zadevne države članice, in sprejme sklep glede razmerja med tveganji in koristmi za zdravilo Prontax 10 mg/ml, raztopina za injiciranje za govedo, ovce in prašiče.
The study was well conducted but not fully in accordance with the guideline on injection site residues (EMEA/CVMP/542/03-FINAL) since a surrounding ring sample was not collected. 
Študija je bila izvedena dobro, vendar ne povsem v skladu s smernico o ostankih na mestu injiciranja (EMEA/CVMP/542/03-FINAL), saj vzorci sosednjega tkiva niso bili zbrani.
Meat and offal: 70 days 
Meso in organi: 70 dni
The applicant Pfizer Limited has submitted an application for a decentralised procedure for Dectomax 10 mg/ml solution for cattle, sheep, and pigs. 
Predlagatelj družba Pfizer Limited je predložil vlogo za decentralizirani postopek za zdravilo Dectomax 10 mg/ml, raztopina za govedo, ovce in prašiče.
The concentration of parent drug in faeces peaked at 3 days after administration (319 μg/kg) with a concentration of 133 µg/kg at 14 days (last sampling point). 
Koncentracija matičnega zdravila v blatu je dosegla najvišjo vrednost 3. dan po dajanju zdravila (319 μg/kg), 14. dan (zadnja točka vzorčenja) pa je znašala 133 µg/kg.
The outcome of the ERA for cattle indicates that the RQs are higher than 1 in the Tier A assessment in two cases, namely daphnids (following direct excretion scenario) and dung fauna. 
Izid ocene tveganja za okolje za govedo kaže, da je količnik tveganja pri ocenjevanju v stopnji A večji od 1 v dveh primerih, in sicer pri dafnidih (pri scenariju neposrednega izločanja) in pri organizmih, prisotnih v gnoju.
• During this referral procedure in Ireland the marketing authorisations of the two reference products Dectomax 1% w/v solution for injection for cattle and sheep and Dectomax 10 mg/ml solution for injection for pigs were transferred from Pfizer Healthcare Ireland to Elanco Animal Health, Eli Lilly and Company Limited and the names of the reference products in Ireland were changed to Zearl 10 mg/ml solution for injection for cattle and sheep and Zearl 10 mg/ml solution for injection for pigs). 
• Med napotitvenim postopkom na Irskem sta bili dovoljenji za promet z referenčnima zdraviloma Dectomax 1 % m/v, raztopina za injiciranje za govedo in ovce, in Dectomax 10 mg/ml, raztopina za injiciranje za prašiče, preneseni z družbe Pfizer Healthcare Ireland na družbe Elanco Animal Health, Eli Lilly in Company Limited, imeni referenčnih zdravil na Irskem pa sta bili spremenjeni v Zearl 10 mg/ml, raztopina za injiciranje za govedo in ovce, in Zearl 10 mg/ml, raztopina za injiciranje za prašiče.
The risk characterisation for dung fauna was performed using Predicted Environmental Concentrations (PECs) for dung, which were derived using the metabolism study provided. 
Opredelitev tveganj za organizme, prisotne v gnoju, je bila izvedena s predvidenimi koncentracijami v okolju (PKO) za gnoj, ki izhajajo iz predložene študije presnove.
Based on the Predicted No Effect Concentrations (PNECs) derived from the LC50 of 1.34 µg/kg soil for horn flies (Haematobia irritans) and the NOEC of 4.0 µg/kg soil for dung beetles (Ontophagus gazelle) the resulting risk quotients (RQs) for both species were high (41940 and 1405, respectively, based on the amount of total residues in dung at day 5 after administration), indicating a high acute risk to dung insects in Tier A. Consequently a Tier B assessment should be performed. 
Na osnovi predvidenih koncentracij brez učinka (PKBU), izpeljanih iz vrednosti LC50 1,34 µg/kg prsti za muho Haematobia irritans, in koncentracije brez opaznega učinka (KBOU) 4,0 µg/kg prsti za govnača (Ontophagus gazelle) sta bila izračunana količnika tveganja (RQ) za obe vrsti visoka (41940 za Haematobia irritans oziroma 1405 za Ontophagus gazelle, na osnovi celotnih ostankov v gnoju 5. dan po dajanju zdravila), kar kaže na visoko akutno tveganje za insekte, prisotne v gnoju, na stopnji A. Posledično bi bilo treba izvesti oceno stopnje B. Vendar pa je znano, da usklajena navodila za izvedbo ocenjevanja tveganja v stopnji B za insekte, prisotne v gnoju, trenutno niso na voljo.
In terms of bioaccumulation the log Pow value is not considered to be robust given the method employed (shake flask). 
Kar zadeva biološko kopičenje, vrednost log Pow zaradi uporabljene metode (stresanje bučke) ni bila ocenjena za zanesljivo.
Grounds for amendments of the product information 
Podlaga za dopolnilo informacij o zdravilu
Conclusions on the benefit-risk balance 
Zaključki o razmerju med tveganji in koristmi
The study is not in accordance with the Note for guidance on injection site residues (EMEA/CVMP/542/03-FINAL) as the injection site was not sampled as recommended in the current guideline (i.e. with a separate core plus surrounding tissue) and the sample weight was low, only between 201-359 g. 
Študija ni skladna z navodilom o ostankih na mestu injiciranja (EMEA/CVMP/542/03-FINAL), saj mesto injiciranja ni bilo vzorčeno v skladu s priporočili iz veljavne smernice (tj. z ločenim jedrom in sosednjim tkivom), poleg tega je bila masa vzorcev majhna, in sicer le 201-359 g.
Based on Predicted Environmental Concentrations for surface water PECsw of 0.0005 g doramectin/l surface water (run-off scenario) and PECsw of 0.209 g doramectin/l surface water (direct excretion) an acute risk for Daphnia was identified in Tier A for both exposure scenarios with risk quotients (RQ) of 5 and 2090, respectively. 
Na osnovi predvidenih koncentracij v okolju za površinske vode PKOpovršinske vode 0,0005 µg doramektina/l površinske vode (scenarij odtekanja) oziroma PKOpovršinske vode 0,209 µg doramektina/l površinske vode (neposredno izločanje) je bilo ugotovljeno akutno tveganje za organizem Daphnia na stopnji A pri obeh scenarijih izpostavljenosti s količnikoma tveganja (RQ) 5 za prvi scenarij oziroma 2090 za drugi scenarij.
The referral for Prontax 10 mg/ml solution for injection for injection for cattle, sheep and pigs relates to the potential serious risks raised by France and the Netherlands regarding the environmental risk assessment (ERA) and by the Netherlands regarding the proposed withdrawal period for cattle. 
Napotitveni postopek za zdravilo Prontax 10 mg/ml, raztopina za injiciranje za govedo, ovce in prašiče, se nanaša na možno resno tveganje v zvezi z oceno tveganja za okolje, na kar sta opozorili Francija in Nizozemska, ter na predlagano karenco za govedo, na kar je opozorila Nizozemska.
Recommended dose 
Pot uporabe Priporočeni odmerek
This results in a withdrawal period of 70 days. 
Tako je karenca 70 dni.
The study is not in accordance with the CVMP Note for guidance on the approach towards harmonisation of withdrawal periods (EMEA/CVMP/036/95/final) and the guideline on injection site residues (EMEA/CVMP/542/03-FINAL) as the injection site was not sampled as recommended in the current guideline (i.e. with a separate core plus its surrounding tissue). 
Študija ni skladna z navodilom CVMP o pristopu k usklajevanju karenc (EMEA/CVMP/036/95/final) in navodilom o ostankih na mestu injiciranja (EMEA/CVMP/542/03-FINAL), saj mesto injiciranja ni bilo vzorčeno v skladu s priporočili iz veljavne smernice (tj. z ločenim jedrom in sosednjim tkivom).
Seven residue studies were made available and assessed by the CVMP for the evaluation of the withdrawal period for cattle. 
Za vrednotenje karence za govedo je CVMP preučil sedem posredovanih študij ostankov.
Prontax 10 mg/ml solution for injection for cattle, sheep, and pigs and associated names is a sterile solution for injection containing doramectin 10 mg per ml. 
Zdravilo Prontax 10 mg/ml, raztopina za injiciranje za govedo, ovce in prašiče, in povezana imena je sterilna raztopina za injiciranje, ki vsebuje doramektin 10 mg/ml.
The n-octanol/water coefficient (log Pow) was determined as 4.4 using the shake flask method. 
Z uporabo metode stresanja bučke je bila ugotovljena vrednost koeficienta n-oktanol/voda (log Pow) 4,4.
• During the decentralised procedure the proposed product name was changed from Dectomax 10 mg/ml solution for injection for cattle, sheep and pigs to Prontax 10 mg/ml solution for injection for cattle, sheep and pigs 
• Med decentraliziranim postopkom je bilo predlagano ime zdravila Dectomax 10 mg/ml, raztopina za injiciranje za govedo, ovce in prašiče, spremenjeno v Prontax 10 mg/ml, raztopina za injiciranje za govedo, ovce in prašiče1.
The reference products for this generic application were Dectomax 1% w/v solution for injection for cattle and sheep and Dectomax 10 mg/ml solution for injection for pigs. 
Referenčni zdravili pri tej generični vlogi sta bili zdravilo Dectomax 1 % m/v, raztopina za injiciranje za govedo in ovce, ter zdravilo Dectomax 10 mg/ml, raztopina za injiciranje za prašiče.
In sheep, the product is intended for the treatment and control of Psoroptes ovis (sheep scab mite) and for the treatment and control of gastrointestinal roundworms and nasal bots. 
Pri ovcah je zdravilo namenjeno za zdravljenje in nadzor infestacij s pršicami Psoroptes ovis (pršica, ki povzroča ovčje garje) ter za zdravljenje in nadzor infestacij s želodčno-črevesnimi glistami in nosnimi zolji.
Withdrawal period for cattle 
Karenca za govedo
A withdrawal period of 63 days has been established for cattle for the reference product. 
Za govedo je bila za referenčno zdravilo določena karenca 63 dni.
In pigs, the product is intended for the treatment of mange mites, gastrointestinal roundworms, lungworms, kidney worms and sucking lice. 
Pri prašičih je zdravilo namenjeno za zdravljenje infestacij z garjami, želodčno-črevesnimi glistami, pljučnimi črvi, ledvičnimi črvi in sesajočimi ušmi.
In cattle, the product is intended for the treatment and control of gastrointestinal roundworms, lungworms, eyeworms, warbles, lice and mange mites. 
Pri govedu je zdravilo namenjeno za zdravljenje in nadzor infestacij z želodčno-črevesnimi glistami, pljučnimi črvi, očesnimi črvi, ličinkami zolja, ušmi in garjami.
Prontax 10 mg/ml solution for injection for cattle, sheep and pigs contains doramectin as active ingredient. 
Zdravilo Prontax 10 mg/ml, raztopina za injiciranje za govedo, ovce in prašiče, vsebuje zdravilno učinkovino doramektin.
The ERA for pigs can stop at Phase I in accordance with the VICH guideline. 
Ocena tveganja za okolje za prašiče se v skladu s smernico VICH lahko zaključi v fazi I. Za govedo in ovce je bilo potrebno ocenjevanje stopnje A faze II.
Overall summary of the scientific evaluation of Prontax 10 mg/ml solution for injection for cattle, sheep, and pigs and associated names 
Splošni povzetek znanstvenega vrednotenja zdravila Prontax 10 mg/ml, raztopina za injiciranje za govedo, ovce in prašiče, in povezanih imen
Kidney: 60 μg/kg 
60 μg/kg
Amendments in the relevant sections of the summary of product characteristics, labelling and package leaflet 
Dopolnila, ki se vključijo v ustrezna poglavja povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo:
PIGS: Meat and offal:withdrawal period 56 days. 
Meso in organi: 56 dni.
INN/Strength Animal species 
INN/Jakost
Doramectin residues were below muscle MRL at the injection site 35 days after treatment. 
Ostanki doramektina na mestu injiciranja so bili 35. dan po zdravljenju pod mejno vrednostjo ostankov za mišičje.
Doramectin residues were above the muscle MRL at the injection site in all animals at 35 days after administration, which is the last timepoint for which there is data. 
Ostanki doramektina na mestu injiciranja so bili 35. dan po dajanju zdravila, kar je zadnja časovna točka, za katero so na voljo podatki, pri vseh živalih nad mejno vrednostjo ostankov za mišičje.
A GLP tissue depletion study from 2002 performed in cattle (34 animals) following two subcutaneous administrations of doramectin at the recommended dose of 200 µg/kg bw with an interval of 7 days between doses. 
Študija izločanja ostankov iz tkiv, skladna z dobro laboratorijsko prakso, je bila izvedena leta 2002 pri govedu (34 živali) po dveh subkutanih dajanjih doramektina v priporočenem odmerku 200 µg/kg telesne mase, pri čemer je bil razmik med odmerkoma 7 dni.
The individual doramectin residues were below the MRL at the injection sites at 35 days after treatment. 
Ostanki doramektina na mestu injiciranja so bili 35. dan po zdravljenju pri posameznih živalih pod mejno vrednostjo ostankov.
Milk: - The product is not permitted for use in lactating sheep used to produce milk for human consumption. 
Mleko: zdravila se ne sme uporabljati pri živalih v laktaciji katerih mleko se uporablja v prehrani človeka, niti pri ovcah v presušitvi oziroma brejih živalih 70 dni pred porodom.
Individual doramectin residues were still above the muscle MRL at the injection site 49 days after administration, which is the last timepoint for which there is data. 
Ostanki doramektina na mestu injiciranja 49. dan po dajanju zdravila, kar je zadnja časovna točka, za katero so na voljo podatki, so bili pri posameznih živalih še vedno nad mejno vrednostjo ostankov za mišičje.
Milk: - The product is not permitted for use in lactating cows used to produce milk for human consumption. 
Mleko: zdravila se ne sme uporabljati pri živalih v laktaciji katerih mleko se uporablja v prehrani človeka niti pri kravah v presušitvi oziroma brejih telicah 60 dni pred porodom.
A GLP tissue depletion study from 1989 was performed in calves (3 groups of 4 animals) following a single subcutaneous administration of doramectin at the recommended dose of 200 µg/kg bw. 
Študija izločanja ostankov iz tkiv, skladna z dobro laboratorijsko prakso, je bila izvedena leta 1989 pri teletih (3 skupine po 4 živali) po enkratnem subkutanem dajanju doramektina v priporočenem odmerku 200 µg/kg telesne mase.
A non-GLP tissue depletion study from 2003 was performed in cattle (24 animals) following a single subcutaneous administration of doramectin at the recommended dose of 200 µg/kg bw. 
Študija izločanja ostankov iz tkiv, neskladna z dobro laboratorijsko prakso, je bila izvedena leta 2003 pri govedu (24 živali) po enkratnem subkutanem dajanju doramektina v priporočenem odmerku 200 µg/kg telesne mase.
Cattlesubcutaneous 
4.11 Karenca
A GLP tissue depletion study from 1991 was performed in calves (18 animals) following a single subcutaneous administration of doramectin at the recommended dose of 200 µg/kg bw. 
Študija izločanja ostankov iz tkiv, skladna z dobro laboratorijsko prakso, je bila izvedena leta 1991 pri teletih (18 živali) po enkratnem subkutanem dajanju doramektina v priporočenem odmerku 200 µg/kg telesne mase.
According to the VICH Guideline 38 Phase II, a Tier B assessment is required. 
V skladu s smernico VICH 38 za fazo II je potrebno ocenjevanje v stopnji B. V prvem primeru kljub več izboljšanjem PKO tveganja za dafnide pri scenariju neposrednega izločanja ni bilo mogoče izključiti.
Fat: 150 μg/kg 
150 μg/kg jetra:
CATTLE: Meat and offal:withdrawal period: 54 days. 
GOVEDO: Meso in organi: 70 dni.
Liver: 100 μg/kg 
100 μg/kg ledvice:
SHEEP: Meat and offal:withdrawal period: 63 days. 
OVCE: Meso in organi: 70 dni.
Applicant 
subkutano
1 Mean toxin neutralising titre obtained after repeated vaccination of a half dose in rabbits. 
Srednji toksin nevtralizirajoči titer je določen po ponovljeni vakcinaciji s polovičnim odmerkom pri kuncih.
This summary was last updated in 11-2006. 
Ta povzetek je bil nazadnje posodobljen 11-2006.
This side effect usually disappears within one week. 
Ta neželeni učinek navadno izgine v enem tednu.
If pain persists for more than 12 hours after medical examination, the doctor should be contacted again. 
Če bolečina vztraja več kot 12 ur po zdravniškem pregledu, je treba zdravnika ponovno obiskati.
Rarely, hypersensitivity (allergic) reactions may occur, which require treatment. 
Redko lahko pride do reakcij prekomerne občutljivosti (alergije), ki zahtevajo zdravljenje.
The first laboratory study tested the dose needed to provide protection. 
V prvi laboratorijski raziskavi so testirali odmerek, ki je potreben za zagotovitev zaščite.
If someone is accidentally injected with this product, they must seek immediate medical advice even if only a very small amount is injected. 
Če je nekdo nenamerno prejel injekcijo tega zdravila, naj takoj poišče zdravniški nasvet, tudi če je bila vbrizgana zelo majhna količina.
The second injection is given 1 to 2 weeks before the expected date of whelping. 
Drugo injekcijo damo 1 do 2 tedna pred pričakovanim dnevom kotitve.
Accidental injection may cause severe pain and swelling, particularly if injected into a joint or finger - rarely causing the loss of a finger. 
Nenamerno vbrizganje lahko povzroči hudo bolečino in otekanje, predvsem če se zdravilo vbrizga v sklep ali prst - redko povzroči izgubo prsta.
The bitch should be revaccinated in the same way during each pregnancy. 
Psico bi morali na enak način cepiti med vsako ponovno brejostjo.
When exposed to canine herpes virus later in life, the puppies will either not become infected or have a much less serious infection. 
Pri izpostavitvi teh mladičev pasjemu herpesvirusu kasneje v življenju, se ti bodisi ne bodo okužili oziroma bo njihova okužba manj resna.
In one field trial the serological response (antibody production) was measured. 
V enem izmed terenskih preizkušanj (tvorjenje protiteles) so merili serološke reakcije.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) EURICAN HERPES 205 EPAR summary for the public 
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) EURICAN HERPES 205 Povzetek EPAR za javnost
Eurican Herpes 205 has been studied in three laboratory studies and two field trials. 
Zdravilo Eurican Herpes 205 so raziskali v treh laboratorijskih raziskavah in dveh terenskih preizkušanjih.
The first injection is given either when the bitch is on heat or 7 -10 days after the date of mating. 
Prvo injekcijo damo bodisi v času, ko se psica goni, ali od 7 do 10 dni po datumu parjenja.
In the other, a study was made of the effect of vaccination on the ability of bitches to breed in an infected kennel. 
V drugem so raziskovali učinek cepljenja na sposobnost razplajanja psic v okuženem pesjaku.
Information on the prescription status of this product may be found on the labelling. 
Podatki o statusu predpisovanja tega zdravila so odtisnjeni na škatli zdravila.
In the study to show the protection of puppies (from vaccinated bitches) from canine herpes virus, over 80% of the pups from the vaccinated bitches survived.. 
V raziskavi, katere namen je bil pokazati zaščito mladičev (zaradi cepljenja psic) pred pasjim herpesvirusom, je preživelo več kot 80 % mladičev cepljenih psic.
The Committee for Medicinal Products for Veterinary Use (CVMP) agreed that the benefits of Eurican Herpes 205 are greater than any risks to immunise healthy bitches against canine herpes virus. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je mnenja, da so koristi zdravila Eurican Herpes 205 večje od vseh tveganj pri imunizaciji zdravih psic na pasji herpesvirus.
The benefitrisk balance may be found in module 6 of this EPAR. 
Razmerje med koristmi in tveganji je v modulu 6 tega Evropskega javnega poročila o oceni zdravila (EPAR).
The European Commission granted a marketing authorisation valid throughout the European Union, for Eurican Herpes 205 to Merial on 26 March 2001. 
Evropska komisija je dovoljenje za promet z zdravilom Eurican Herpes 205, veljavno po vsej Evropski uniji, odobrila družbi Merial dne 26. marca 2001.
Eurican Herpes 205 is used to immunise pregnant bitches to prevent mortality, clinical signs and lesions in puppies caused by canine herpes virus infections acquired in the first few days of life. 
Eurican Herpes 205 se uporablja za imunizacijo brejih psic, da bi tako preprečili smrtnost, klinične znake in lezije pri mladičih, ki jih povzroči okužba s pasjim herpesvirusom v prvih dneh življenja.
The last one has demonstrating that induction of antibodies is equivalent when bitches are vaccinated the day of heat or 7-10 days after mating. 
Raziskava je pokazala, da je indukcija tvorjenja protiteles ustrezna, če se psice cepi na dan, ko se gonijo, ali od 7 do 10 dni po parjenju.
Here Eurican Herpes 205 was compared with no vaccination (controls). 
V tej raziskavi zdravila Eurican Herpes 205 niso primerjali z drugimi cepivi (kontrola).
Other information about Eurican Herpes 205: 
Druge informacije o zdravilu Eurican Herpes 205:
Eurican Herpes 205 contains the active substance canine herpes virus (F205 strain) antigens in a dose of 0.3 to 1.75 µg. 
Eurican Herpes 205 vsebuje kot zdravilno učinkovino antigene pasjega herpesvirusa (sev F205) v odmerku od 0,3 do 1,75 µg.
The injection of Eurican Herpes 205 may cause temporary oedema (fluid under the skin) at the injection site in up to 10% of animals. 
Injekcija zdravila Eurican Herpes 205 lahko povzroči nastanek začasnega edema (zbiranje tekočine pod kožo) na mestu vbrizganja pri največ 10 % živali.
Eurican Herpes 205 contains mineral oil. 
Zdravilo Eurican Herpes 205 vsebuje mineralno olje.
The second study was carried out to show the protection of puppies from vaccinated bitches from canine herpe svirus. 
Drugo raziskavo so izvedli, da bi dokazali zaščito mladičev pred pasjim herpesvirusom zaradi cepljenja psic.
Eurican Herpes 205 is intended to protect the puppies from this infection during the first few days of life. 
Zdravilo Eurican Herpes 205 je namenjeno za zaščito mladičev pred omenjeno okužbo v prvih dneh življenja.
Eurican Herpes 205 is a powder and solvent that is made into an emulsion for injection. 
Eurican Herpes 205 sestavljata prašek in vehikel za pripravo emulzije za injiciranje.
Eurican Herpes 205 is given as two 1 ml subcutaneous (under the skin) doses. 
Eurican Herpes 205 damo kot dva 1 ml podkožna (subkutana) odmerka.
Eurican Herpes 205 showed good protection from canine herpes virus. 
Zdravilo Eurican Herpes 205 je pokazalo dobro sposobnost zaščite pred pasjim herpesvirusom.
What benefit has Eurican Herpes 205 shown during the studies? 
Kakšne koristi je zdravilo Eurican Herpes 205 izkazalo med raziskavami?
The Package Leaflet should be taken to the doctor. 
K zdravniku nesite tudi Navodilo za uporabo.